MX385381B - Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). - Google Patents

Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).

Info

Publication number
MX385381B
MX385381B MX2018010334A MX2018010334A MX385381B MX 385381 B MX385381 B MX 385381B MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 385381 B MX385381 B MX 385381B
Authority
MX
Mexico
Prior art keywords
compound
jak
crystal
inhibitory activity
janus kinase
Prior art date
Application number
MX2018010334A
Other languages
English (en)
Other versions
MX2018010334A (es
Inventor
Fumi Higuchi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2018010334A publication Critical patent/MX2018010334A/es
Publication of MX385381B publication Critical patent/MX385381B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un objeto de la presente invención es proporcionar un compuesto con una excelente actividad inhibidora de JAK1. El compuesto de la invención tiene actividad inhibidora de JAK1, y por lo tanto, efecto inmunosupresor, efecto antiinflamatorio, efecto antiproliferativo, etc., y es útil en el tratamiento de las enfermedades, por ejemplo, artritis reumatoide, enfermedad inflamatoria intestinal, psoriasis, vasculitis, asma bronquial, enfermedad pulmonar obstructiva crónica, sinusitis eosinofílica y pólipo nasal.
MX2018010334A 2016-03-01 2017-02-28 Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). MX385381B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016039315 2016-03-01
PCT/JP2017/007594 WO2017150477A1 (ja) 2016-03-01 2017-02-28 Ｊａｋ阻害作用を有する化合物の結晶

Publications (2)

Publication Number Publication Date
MX2018010334A MX2018010334A (es) 2018-11-09
MX385381B true MX385381B (es) 2025-03-18

Family

ID=59743962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010334A MX385381B (es) 2016-03-01 2017-02-28 Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).

Country Status (22)

Country Link
US (2) US10822350B2 (es)
EP (1) EP3424930B1 (es)
JP (1) JP6791239B2 (es)
KR (1) KR102653231B1 (es)
CN (1) CN108699082B (es)
BR (1) BR112018016523B1 (es)
CA (3) CA3206830A1 (es)
CY (1) CY1123607T1 (es)
DK (1) DK3424930T3 (es)
ES (1) ES2844978T3 (es)
HR (1) HRP20210062T1 (es)
HU (1) HUE051615T2 (es)
LT (1) LT3424930T (es)
MX (1) MX385381B (es)
PL (1) PL3424930T3 (es)
PT (1) PT3424930T (es)
RS (1) RS61238B1 (es)
RU (1) RU2705721C1 (es)
SI (1) SI3424930T1 (es)
SM (1) SMT202000717T1 (es)
TW (1) TWI712604B (es)
WO (1) WO2017150477A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
BE1028574B1 (nl) * 2020-09-14 2022-12-06 Eurochem Antwerpen Heterocyclische verbindingen gebruikt als nitrificatieremmer
WO2025216268A1 (ja) * 2024-04-09 2025-10-16 国立研究開発法人国立循環器病研究センター 重症肺高血圧症又は膠原病の予防又は治療薬
JP7742516B1 (ja) * 2025-07-31 2025-09-19 日本新薬株式会社 好酸球性多発血管炎性肉芽腫症の処置剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
ZA200802685B (en) * 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
CN102532133A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8524707B2 (en) 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
WO2012037132A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
EP2629777B1 (en) 2010-10-22 2018-12-19 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶

Also Published As

Publication number Publication date
DK3424930T3 (da) 2021-01-11
CN108699082B (zh) 2021-04-09
BR112018016523B1 (pt) 2024-02-06
KR102653231B1 (ko) 2024-04-01
PT3424930T (pt) 2020-12-04
LT3424930T (lt) 2021-01-11
CA3015464C (en) 2024-04-23
HUE051615T2 (hu) 2021-03-01
CA3206830A1 (en) 2017-09-08
CN108699082A (zh) 2018-10-23
WO2017150477A1 (ja) 2017-09-08
US10822350B2 (en) 2020-11-03
SMT202000717T1 (it) 2021-01-05
JPWO2017150477A1 (ja) 2018-12-27
BR112018016523A2 (pt) 2018-12-26
PL3424930T3 (pl) 2021-05-04
TWI712604B (zh) 2020-12-11
RS61238B1 (sr) 2021-01-29
ES2844978T3 (es) 2021-07-23
CA3015464A1 (en) 2017-09-08
TW201731855A (zh) 2017-09-16
EP3424930A1 (en) 2019-01-09
JP6791239B2 (ja) 2020-11-25
CY1123607T1 (el) 2022-03-24
CA3264321A1 (en) 2025-10-30
US11377453B2 (en) 2022-07-05
KR20180116341A (ko) 2018-10-24
EP3424930A4 (en) 2019-07-10
RU2705721C1 (ru) 2019-11-11
US20190048023A1 (en) 2019-02-14
EP3424930B1 (en) 2020-11-04
MX2018010334A (es) 2018-11-09
SI3424930T1 (sl) 2021-01-29
US20210017191A1 (en) 2021-01-21
HRP20210062T1 (hr) 2021-03-05

Similar Documents

Publication Publication Date Title
EA201591462A1 (ru) Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
MX394473B (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
PH12016502099A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
MX385381B (es) Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).
JOP20200086B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما
JO3458B1 (ar) 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
UY37017A (es) Inhibidores aza-bencimidazol de pad4
GEP20186885B (en) Novel compounds
UY35654A (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
CO2017002982A2 (es) Compuesto de pirazolotiazol y medicamento que comprende el mismo
EA201790072A1 (ru) Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы
MX2018005259A (es) Inhibidores de gelatinasa y uso de los mismos.
EA201391155A1 (ru) Ингибитор катепсина с
MX376875B (es) Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.
MX2021015553A (es) Inhibidores de arginasa novedosos.
IL310039A (en) Large scale adeno-associated virus production systems
EP3946349C0 (en) SR-1903 FOR THE TREATMENT OF INFLAMMATORY, INNATE OR AUTOIMMUNE DISORDERS
MX370251B (es) Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
UA113645C2 (xx) ТРИАЗОЛОНИ ЯК ІНГІБІТОРИ mPGES-1